IP Library Granted Patent US 12661376
Granted Patent B2
US 12661376 · App. 17/993,823 · Granted Jun 23, 2026

Optimized cell transplant, and preparation method and use thereof

Inventors: Ruei-Yue Liang (Zhubei, TW); Kai-Ling Zhang (Zhubei, TW); Ming-Hsi Chuang (Zhubei, TW); Po-Cheng Lin (Zhubei, TW); Peggy Leh Jiunn Wong (Zhubei, TW); Chia-Hsin Lee (Zhubei, TW)
Assignee: Gwo Xi Stem Cell Applied Technology Co., Ltd.
A61K35/28C12N5/0667C12N2500/32C12N2500/38C12N2500/60C12N2500/90C12N2501/115C12N2501/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661376
App. No.
17/993,823
Granted
Jun 23, 2026
Kind
B2
Abstract

Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell.

Claims (14)

1 . A preparation method of an optimized cell transplant, for preparing an optimized cell transplant with high survival rate and simultaneous high expression of multiple genes; the preparation method comprising the following steps:

a cell modified culture step: mesenchymal stem cells are cultured in a first medium at a cell density of 6,000-15,000 cells/cm 2 , wherein the surface of a culture dish used has an oxygen-containing functional group and thus features a net negative surface charge due and hydrophilic; the first medium is removed after a first culture time to obtain a modified cell intermediate; and

a cell optimized culture step: the modified cell intermediate is cultured in a second medium, and the second medium is removed after a second culture time to obtain an optimized cell transplant, wherein

the mesenchymal stem cells are any one selected from adipose-derived stem cells, bone marrow stem cells, peripheral blood stem cells and umbilical cord blood stem cells;

the first medium is a serum-free DMEM/F12 medium comprising TGF-b1, FGF-2, hydrocortisone, human serum albumin, L-glutamine, leucine aminopeptidase, an HEPES buffer and lipid;

the first culture time is between 1 day and 10 days;

the second culture time is between 7 days and 28 days;

the optimized cell transplant has simultaneously and highly expressed CD200, Galectin-9 and VISTA genes; and

the expression levels of the CD200, Galectin-9 and VISTA genes of the optimized cell transplant are at least two times higher than those of the mesenchymal stem cells.

2 . The preparation method of the optimized cell transplant according to claim 1 , wherein the expression level of the CD200 gene of the optimized cell transplant is at least 8 times higher than that of the mesenchymal stem cells.

3 . The preparation method of the optimized cell transplant according to claim 1 , wherein the expression level of the Galectin-9 gene of the optimized cell transplant is at least 2 times higher than that of the mesenchymal stem cells.

4 . The preparation method of the optimized cell transplant according to claim 1 , wherein the expression level of the VISTA gene of the optimized cell transplant is at least 2 times higher than that of the mesenchymal stem cells.

5 . The preparation method of the optimized cell transplant according to claim 1 , wherein the survival rate of the optimized cell transplant is 90% or more.

6 . The preparation method of the optimized cell transplant according to claim 1 , wherein the second medium is a serum-free DMEM/F12 medium comprising nicotinamide, exendin-4, pentagastrin, a B-27 serum-free supplement and an N-2 supplement.